89Zr-RO5323441 PET imaging in patients with recurrent glioblastoma treated with bevacizumab
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 26 Aug 2015
At a glance
- Drugs THR 317 (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Pharmacokinetics
- 27 Mar 2014 Trial status changed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 09 Dec 2013 Planned end date changed from 1 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 21 Jun 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01622764).